"Can ERNs become pharma’s platform of choice for Real World Evidence?"

We will be exploring the overlapping challenges and opportunities in collecting clinical data for registries, clinical trials and European Reference Networks (ERNs). George Reynolds will be co-hosting the webinar with Mark Krueger, Founder and Chief Strategy Officer of MK&A and Kay Parkinson CEO of Cambridge Rare Disease Network.

For 23 years, MK&A has had a singular focus on building strong and strategic relationships between pharmaceutical companies and patient organisations. As a parent of children with rare diseases, Kay has been running the Alstrom Syndrome patient organization since 1998. Last year Vitro Software jointly won the European Commission’s tender to supply the IT platform for all 24 ERNs.

This webinar is timely because of the strong interest in ERNs within the Orphan Drug community and because of the current EURORDIS drive to set up CABs. Community Action Boards are designed to encourage patient and pharma collaboration in setting up clinical studies.

The webinar will take place on the 2nd of October 2018, 16:00 – 17:30 CET (10:00 EST, 15:00 GMT). Register to attend "Can ERNs become pharma's platform of choice for RWD" webinar.